Blog Posts

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Photo tsaken from Samarpana Chakraborty/X

Aug 10, 2024, 13:03

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Samarpana Chakraborty, Postdoctoral Researcher at Albert Einstein College of Medicine shared a post by Aditi Shastri, Associate Professor at Albert Einstein College of Medicine on X:

“Thrilled to share my postdoctoral work on STAT3 degraders in Venetoclax resistant AML. Grateful to Shastri lab and Aditi Shastri for giving me the opportunity to work on this fantastic project. ”

Quoting Aditi Shastri’s post:

“A new manuscript from shastri lab just dropped “A STAT3 Degrader Demonstrates Preclinical Efficacy in Venetoclax Resistant AML”. Congratulations to first author Samarpana Chakraborty and a huge thanks to amazing collabs and Kymera Therapeutics, EinsteinSCI, and Montefiore Health System.”

Source: Samarpana Chakraborty/X and Aditi Shastri/X

Aditi Shastri Albert Einstein College of Medicine cancer EinsteinSCI Kymera Therapeutics Montefiore Health System OncoDaily Oncology Samarpana Chakraborty

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...